• Wed, December 11, 2024

by: The Motley Fool UK

2 FTSE 100 shares I plan to avoid like the plague in 2025

Mark Hartley identifies two FTSE 100 shares he wouldn't go near in 2025, explaining why their fundamentals don't align with his strategy.

by: U.S. News & World Report

7 Growth Stocks That Also Pay Dividends

AAPL is one of the best-known and most widely held dividend-paying growth stocks in the world. This tech giant has a market cap of about $3.7 trillion. Wall Street estimates that the company will generate about $414 billion in revenue during its current fiscal year and grow that number by 8% to $448 billion in fiscal 2026.

by: CBS News

Inflation is rising again: Why you should invest in gold now

By adding gold to your portfolio, you can not only safeguard your wealth against rising inflation but also bolster your financial resilience in an unpredictable economic landscape. As inflation ticks upward again, now may be the ideal time to consider this time-tested investment.

by: The Globe and Mail

Market Factors: The most interesting lookahead to 2025 that I've seen

Market Factors features the best, most interesting lookahead to 2025 in this edition. Meanwhile, Scotiabank strategists provide optimism for income investors while U.S. "Freedom Cities" provide the diversion.

by: USA Today

Intel's stock did something it hasn't done since 2022

However, after taking a close look at Intel's price movement, there could be some reasons to believe the stock is positioned for a rebound. Below, I'm going to explore something that Intel's stock hasn't done since 2022 and make the case for why I'm cautiously optimistic that better days could be in store for the chipmaker.

by: Kiplinger

Stock Market Today: Tech Stocks Rally as CPI Supports Lower Rates

Core CPI, which excludes food and energy costs and is considered a better indicator of future prices, also matched estimates. The gauge increased 0.3% in November, or the same rate seen over the previous three months. Annual core CPI advanced 3.3% to match consensus expectations.

by: Forbes

6 Best Value Stocks To Buy In 2025

Looking for the best value stocks to buy in 2025? Here's a list of top value stock picks to help bolster your portfolio.

by: The Motley Fool Canada

1 Reliable Dividend Stock for the Ultimate Retirement Income Stream

Stocks that give investors a raise every year are attractive for helping retirees increase their income. It can be a form of built-in inflation protection for your investments, and top dividend-growth stocks typically deliver long-term capital gains.

by: The Australian Financial Review

How to pick the ASX's next dividend winners

Private wealth firm Wilsons Advisory says there's more to it than just buying a stock with a high dividend yield.

by: Investopedia

Top Stock Movers Now: Google Parent Alphabet, Netflix, Tesla, and More

Major U.S. indexes gained at midday Wednesday as tech stocks climbed after the latest report on consumer inflation reinforced expectations the Federal Reserve will cut its key interest rate next week.

by: MSN

Why Is AirSculpt Technologies Inc. (AIRS) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are going to take a look at where AirSculpt Technologies Inc. (NASDAQ:AIRS) stands against the other cosmetic surgery and aesthetics stocks.

by: Insider Monkey

How Rezolve AI (RZLV) is Changing E-Commerce with AI and Conversational Apps

As artificial intelligence continues to reshape industries, experts are increasingly focusing on how its integration will impact investment strategies.

by: Insider Monkey

Super Micro Computer (SMCI): Navigating AI Growth and Financial Scandals

We recently compiled a list of the 10 AI News Investors Probably Missed. In this article, we are going to take a look at where Super Micro Computer, Inc.

by: The Motley Fool

Billionaire Warren Buffett Owns 45 Stocks and ETFs. But Only One Has a Beefy 5% Dividend Yield.

Buffett's company Berkshire Hathaway owns several high-yielding stocks in its portfolio. However, of the 45 stocks and exchange-traded funds exchange-traded funds (ETFs) Berkshire owns, only one has a dividend yield above 5% -- and it's a stock Buffett has owned for over a decade.

by: The Motley Fool Canada

Short-Selling on the TSX: The Stocks Investors Are Betting Against

High-risk investors engage in short-selling, betting against some TSX stocks for bigger profits. The widely used strategy to make money from stocks is to buy low and sell high. You buy at the lowest price point possible, then unload at a much higher price to maximize profits. However, some investors profit from falling share prices.

by: MSN

Why Is Apyx Medical Corporation (APYX) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are going to take a look at where Apyx Medical Corporation (NASDAQ:APYX) stands against the other cosmetic surgery and aesthetics stocks.

by: U.S. News & World Report

NYSE's Lynn Martin Sees Active IPO Market in 2025

NEW YORK (Reuters) - The market for U.S. initial public offerings could see high levels of interest from investors next year, said Lynn Martin, president of the New York Stock Exchange on Wednesday at the Reuters NEXT conference in New York. "We are shaping up for a really active 2025," she said.

by: Insider Monkey

Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers

We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Intellia Therapeutics, Inc.

by: U.S. News & World Report

8 Best Quantum Computing Stocks to Buy for 2025

The company also announced that third-quarter 2024 revenue stood at $12.4 million, up 102% on a year-to-year basis. With momentum on its side, ample cash reserves and some heavy hitters in its corner, IonQ is rolling strong into 2025, and shareholders may want to roll with it.

by: The Motley Fool

Here's My Favorite Warren Buffett Stock Heading Into 2025 and Beyond

One stock in particular that I consider my favorite in Berkshire Hathaway's portfolio is Visa ( V 1.32%). Although it's not one of its top holdings, Visa has a competitive advantage and growth projections that make it a good choice to be a staple in many investors' portfolios for quite some time.

by: The Motley Fool Canada

2024's Top Canadian Dividend Stocks to Hold Into 2025

Canadian Natural Resources ( TSX:CNQ) should be on your radar for worry-free and growing passive income in 2025. This oil and gas company has been increasing its dividend at a stellar rate. For instance, the energy company has raised its dividend at a CAGR of 21% in the past 25 years. Moreover, it offers an attractive yield of over 4.6%.

by: MSN

2 ASX 200 shares I think will bounce back in 2025

These stocks have had a tough 2024. The post 2 ASX 200 shares I think will bounce back in 2025 appeared first on The Motley Fool Australia.

by: Business Insider

Oppenheimer sets Wall Street's highest S&P 500 price target as it eyes 17% upside for stocks in 2025

Oppenheimer sees the S&P 500 climbing to 7,100 by the end of next year, vaulting past predictions from other top forecasters.

by: The Motley Fool

Will Palantir Technologies Stock Continue Its Red-Hot Rally in 2025?

Palantir's business has been booming as artificial intelligence (AI) elevated the company's offerings, leading to a surge in demand, and multiple quarters of impressive results. But is this tech stock still a no-brainer buy heading into 2025?

by: MSN

Dividend Investing: 5 Must-Have High-Yield S&P 500 Stocks for 2025

The U.S. markets in 2024 navigated a complex landscape marked by economic recovery, shifting monetary policies, and global uncertainties. Despite challenges, the year showcased resilience across key sectors and highlighted emerging trends that shaped market performance.

by: Insider Monkey

Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900

We recently published a list of Jim Cramer's Latest Calls: Top 10 Stocks. In this article, we are going to take a look at where Eli Lilly And Co (NYSE:LLY) stands against other stocks highlighted in Jim Cramer's latest calls.

by: The Motley Fool Canada

3 Top Small-Cap Stocks to Buy for Next 3 Years

These Canadian small-cap companies are poised to grow significantly and could deliver stellar returns over the next three years.

by: The Motley Fool

Should You Buy Palo Alto Networks Before Its Stock Split?

One popular pick in this space is Palo Alto Networks ( PANW 0.21%), a company that is set to split its stock on Dec. 16. With an impending stock split, many investors may be wondering if Palo Alto Networks is a good buy right now, especially since cybersecurity stocks are a popular investing space.

by: MSN

Why Baker Hughes (BKR) Is One of the Most Profitable Natural Gas Stocks to Invest in?

We recently published a list of 8 Most Profitable Natural Gas Stocks To Invest In. In this article, we are going to look at where Baker Hughes Company (NASDAQ:BKR) stands against other most profitable natural gas stocks to invest in.

by: MSN

Barclays cuts homebuilding stocks on flattening home prices, elevated incentives

Barclays (LON:BARC) on Wednesday downgraded the ratings of some U.S. homebuilding stocks DR Horton Inc (NYSE:DHI), Lennar Corporation (NYSE:LEN), PulteGroup Inc (NYSE:PHM) and KB Home (NYSE:KBH) from Overweight to Equal Weight as it expects

by: MSN

Top 5 ETF categories to watch in 2025

As of November 2024, the year-to-date net inflows for U.S.- listed ETFs was $915 billion, setting a new annual record, according to data from VettaFi. But which ETF categories are likely to capture investors' attention heading into the new year?

by: Seeking Alpha

Gold: I'd Love To Be Bullish, But Not At These Levels

Gold trades above fair value, signaling potential headwinds. Read why TIPS, Treasuries, and commodities are poised for better performance than gold.

by: Seeking Alpha

EQWL: A Low-Valuation Equal-Weight ETF, Outperforming Peers But Lagging The S&P 500 Index

Funds using an equal-weight approach come out as an interesting option to diversify risk and mitigate excess volatility. Read an analysis of EQWL ETF here.

by: Seeking Alpha

BE Semiconductor: A Market Leader With Enormous Dividend Growth Potential

Despite the sharp drop in share price since February 2024, BESIY's fundamentals are still intact. Explore more details here.

by: Seeking Alpha

Verizon: Narrow Margin Of Safety Per Graham P/E And Number

Verizon's Q3 2024 earnings, reiterates HOLD rating due to tepid growth prospects and slim margin of safety. Explore more details here.

by: Seeking Alpha

2 Great BDCs, Up To 10% Yield, For A Bright And Merry Christmas

Business development companies play a pivotal role in the economy, during both slowdowns and upturns. Read more to see my 2 BDC picks.

by: Seeking Alpha

Oracle: The Market Has Given Us An Early Christmas Present (Rating Upgrade)

Oracle's growth momentum remains strong despite short-term setbacks. Read why ORCL stock's post-earnings decline is a chance for cloud and AI investors.

by: Seeking Alpha

Southwest Airlines Will Deliver Great News Into 2025 And Beyond

Southwest's strong balance sheet allows for continued dividends and share repurchases, positioning it well for future growth despite recent challenges. Read more here.

by: Seeking Alpha

Immunome: A Recently Acquired Lead Asset And A Small Market

Immunome has a turbulent history, shifting focus from COVID-19 therapies to oncology. Read what the future may hold for this small-cap biotech. Learn more on IMNM stock here.

by: Seeking Alpha

UiPath: AI And The Path To More Cash Flow

UiPath's valuation at 29x forward free cash flow reasonable given its significant cash position. Click here to read an analysis of PATH stock now.

by: Seeking Alpha

Allianz: Neutral View After Capital Market Day

Allianz's CMD update meets Wall Street expectations, but with minimal EPS growth and stagnant shareholder remuneration. See why a neutral rating is advised on ALIZF.

by: Seeking Alpha

Chord Energy: Stock Repurchases, Sale Of Assets, Synergies, And Extremely Cheap

Chord Energy Corporation's recent merger and asset sales are expected to enhance cash flow and balance sheet, making CHRD appear undervalued. Read more here.

by: Seeking Alpha

Ollie's Bargain Outlet: Robust Performance Deserves A Premium Multiple (Rating Upgrade)

I recommended a hold rating for Ollie's Bargain Outlet (OLLI) stock when I wrote about it on 12th Sept. See why we upgraded my valuation to a buy currently.

by: Seeking Alpha

International Seaways: Well-Diversified Across Multiple Tanker Market Segments

International Seaways operates a diversified fleet of 76 tankers, in addition to six Long Range 1 (LR1) newbuilds. Read why I'm bullish on INSW stock.

by: Seeking Alpha

Yext: Still Missing The Target (Rating Downgrade)

Yext's focus on profitability over growth has led to missed opportunities in booming AI search market. See why I downgrade YEXT stock from strong buy to hold.

by: Seeking Alpha

DNP: Big Income, Market Crash Hedge

The DNP Select Income Fund is a high-yield closed-end fund offering a hedge against stock market crashes. Learn more about DNP CEF here.

by: Seeking Alpha

CVS: Why I'm Selling My Worst Holding Of 2024

CVS stock has been a challenging investment due to industry turmoil and legal challenges. Read more on how investors may view CVS today and in the future.

by: Seeking Alpha

Cash COWs And Buried Treasures: 2024 Performance Review

Cash COWs and Buried Treasures portfolios outperform market indices, offering high yields and strong dividend safety for investors. Explore more details here.

Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900

We recently published a list of Jim Cramer's Latest Calls: Top 10 Stocks. In this article, we are going to take a look at where Eli Lilly And Co (NYSE:LLY) stands against other stocks highlighted in Jim Cramer's latest calls.
Jim Cramer, a prominent financial commentator, has expressed a strong preference for Eli Lilly (LLY) over Regeneron Pharmaceuticals, even if Eli Lilly's stock price were to reach $900 per share. In his analysis, Cramer highlights Eli Lilly's robust pipeline and its potential in the obesity and diabetes markets, particularly with drugs like Mounjaro, which has shown promising results. He contrasts this with Regeneron, noting that while it has successful products like Eylea for eye diseases, its future growth might not match Eli Lilly's due to less diversified and less expansive upcoming treatments. Cramer's endorsement of Eli Lilly is based on its innovation, market positioning, and the significant impact its new drugs could have on its revenue and stock performance.

Read the Full Insider Monkey Article at:
https://www.insidermonkey.com/blog/jim-cramer-says-he-would-prefer-eli-lilly-lly-over-regeneron-even-at-900-1405891/